How does POLB.F's PB Ratio compare to its peers?

POLB.F is expensive based on its Price-To-Book Ratio (3x) compared to the peer average (2.3x).

How does POLB.F's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

POLB.F is expensive based on its Price-To-Book Ratio (3x) compared to the US Pharmaceuticals industry average (1.8x).

What is POLB.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate POLB.F's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of POLB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate POLB.F's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Poolbeg Pharma (OTCPK:POLB.F) - Stock Price, News & Analysis

POLB.F Stock Overview

Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. More details

POLB.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 13.1% per year for the next 3 years

Makes less than USD$1m in revenue (£0)

Shares are highly illiquid

Does not have a meaningful market cap ($37M)

+ 1 more risk

Poolbeg Pharma PLC Competitors

Cannabist Company Holdings

OTCPK:CBST.F

US$52.0m

BGM Group

NasdaqCM:BGM

US$63.1m

CalciMedica

NasdaqCM:CALC

US$46.5m

SCYNEXIS

NasdaqGM:SCYX

US$52.0m

Price History & Performance

Summary of all time highs, changes and price drops for Poolbeg Pharma
Historical stock prices
Current Share Price	UK£0.12
52 Week High	UK£0.23
52 Week Low	UK£0.11
Beta	2.14
11 Month Change	-21.85%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	18.00%

Recent updates

Shareholder Returns

	POLB.F	US Pharmaceuticals	US Market
7D	0%	2.8%	1.0%
1Y	n/a	13.3%	31.4%

Return vs Industry: Insufficient data to determine how POLB.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how POLB.F performed against the US Market.

Price Volatility

Is POLB.F's price volatile compared to industry and market?
POLB.F volatility
POLB.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: POLB.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine POLB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2021	15	Jeremy Skillington	www.poolbegpharma.com

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.

Poolbeg Pharma PLC Fundamentals Summary

How do Poolbeg Pharma's earnings and revenue compare to its market cap?
POLB.F fundamental statistics
Market cap	US$46.66m
Earnings (TTM)	-US$5.56m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.4x

P/E Ratio

Is POLB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
POLB.F income statement (TTM)
Revenue	UK£0
Cost of Revenue	UK£0
Gross Profit	UK£0
Other Expenses	UK£4.38m
Earnings	-UK£4.38m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0088
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did POLB.F perform over the long term?

See historical performance and comparison

POLB.F Stock Overview

Risk Analysis

Poolbeg Pharma PLC Competitors

OTCPK:CBST.F

US$52.0m

NasdaqCM:BGM

US$63.1m

NasdaqCM:CALC

US$46.5m

NasdaqGM:SCYX

US$52.0m

Price History & Performance

Recent News & Updates

Poolbeg Pharma plc Announces U.S. Patent Office Grants U.S. Immunomodulator I Patent

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

Recent updates

Poolbeg Pharma plc Announces U.S. Patent Office Grants U.S. Immunomodulator I Patent

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Shareholder Returns

Price Volatility

About the Company

Poolbeg Pharma PLC Fundamentals Summary

0.0x

-8.4x

Earnings & Revenue